ADXS NEO

Drug Profile

ADXS NEO

Alternative Names: ADXS-NEO; Neoepitope-based immunotherapies - Advaxis

Latest Information Update: 17 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Advaxis; Memorial Sloan-Kettering Cancer Center
  • Developer Advaxis; Amgen; Memorial Sloan-Kettering Cancer Center
  • Class Cancer vaccines; Gene therapies; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Gene transference; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Colorectal cancer; Head and neck cancer; Non-small cell lung cancer
  • Preclinical Cancer

Most Recent Events

  • 11 May 2018 Preclinical pharmacodynamics data in Cancer released by Advaxis
  • 01 Mar 2018 Phase-I clinical trials in Non-small cell lung cancer, Head and neck cancer and Colorectal cancer (Metastatic disease) in USA (Parenteral) (NCT03265080)
  • 21 Dec 2017 Advaxis has patents pending for ADXS NEO in countries worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top